11:05 AM EDT, 08/26/2025 (MT Newswires) -- Eli Lilly's ( LLY ) investigational oral drug orforglipron met its primary endpoint in a phase 3 trial in patients with type 2 diabetes and obesity, strengthening the case for regulatory approval and signaling significant revenue potential, Truist Securities said in a note Tuesday.

The firm said the trial is the second late-stage trial success for orforglipron, supporting filing for US Food and Drug Administration approval, though competition in the obesity market is expected to intensify.

Truist estimates worldwide peak sales of $14.7 billion for the drug versus $11.7 billion consensus, calling it a "double-digit billion dollar opportunity" given its safety profile and ease of manufacturing.

The market is expected to eventually become segmented based on patient characteristics, weight loss needed to get to a healthy BMI, and patients' tolerance to specific therapies, analysts said.

Truist has a buy rating on the stock and $1,038 price target.

Shares of Eli Lilly ( LLY ) were up more than 2% in recent trading Tuesday.

Price: 714.51, Change: +19.18, Percent Change: +2.76